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A B S T R A C T
Visceral Leishmaniasis (VL) is an opportunistic infection amongst HIV-infected people in several
endemic countries, and the clinical management of this co-infection poses several challenges. Here we
describe a co-infected patient in India who failed to respond to miltefosine monotherapy and
subsequently relapsed following two further (different) regimens of liposomal amphotericin B. He was
then successfully treated with a combination of 30 mg/kg liposomal amphotericin B and 14 days of
100 mg/day oral miltefosine.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Leishmaniasis and Human Immunodeﬁciency Virus (HIV) co-
infection has gained clinical importance in several African
countries where both infections are endemic. Host defense
against leishmaniasis in general, and Leishmania donovani in
particular, is T-cell dependent. Accordingly, patients with HIV
infection are not only more susceptible to leishmaniasis but also
present signiﬁcant diagnostic and therapeutic challenges. Chief
among the difﬁculties are that clinical presentation of VL in co-
infected patients may be relatively unspeciﬁc, and that therapeu-
tic failure and relapse are more common. Furthermore, from a
public health perspective, managing these patients effectively
has serious implications with respect to VL elimination strategies
in areas where disease burdens of HIV and VL overlap.
Single-dose 10 mg/kg liposomal amphotericin B is currently the
WHO-recommended ﬁrst-line treatment for VL in the Indian sub-
continent1. However, its efﬁcacy in HIV co-infected patients has
not been documented, nor are there established guidelines or
randomized controlled trials to guide decisions about treatment
for these patients. Furthermore, high relapse rates and difﬁculty
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).well-described, yet there is also very little evidence available
regarding best treatment strategies following relapse2. In this
short communication we describe the successful treatment of a
co-infected patient using a combination of existing therapies,
after the failure of three successive monotherapies.
2. Case report
A 43-year old male from Jharkhand (a state in Eastern India
endemic for VL) presented to a local hospital with a 6-month
history of low-grade fever and malaise associated with anorexia
and weight loss. He was diagnosed with both HIV-1 infection
(based on serial serology testing) and visceral leishmaniasis (based
on rK-39 serology), and started a 28-day course of oral miltefosine
at 100 mg/day divided into two doses, as per the Indian national
guidelines for VL treatment. He did not initiate antiretroviral
therapy (ART) at this stage.
Despite improving after completing this treatment, he pre-
sented within three months to the Christian Medical College in
Vellore with a recurrence of fever, fatigue and weight loss. Physical
examination demonstrated pallor and enlarged liver and spleen,
5 cm and 8 cm below the costal margin, respectively. Laboratory
evaluation revealed a hemoglobin of 8.2 gm/dl, total WBC 8200
cells/mm3, platelets of 86 x109/l, and a CD4 count of 127 cells/ul.
Bone marrow aspiration conﬁrmed Leishmania donovani. The
patient was treated for VL using a single dose of 10 mg/kg
intravenous liposomal amphotericin B (AmBisome, Gilead, USA).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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for HIV/VL co-infection by WHO in 20101, a recommendation
based primarily on experience of L.infantum and HIV co-infection
in Europe. The 10 mg/kg single-dose regimen was previously
shown to be highly effective in the Indian context, albeit in
immunocompetent patients3. In addition, the patient was started
on tenofovir, emtricitabane and efavirenz for HIV, plus cotrimox-
azole prophylaxis. He responded well and was discharged as an
initial cure following the VL treatment.
At the 3-month follow-up, although afebrile, the patient was
found to have increased splenomegaly despite reporting full
adherence to HIV ART. A repeat bone marrow examination again
demonstrated L. donovani bodies, and CD4 count was 121 cells/uL.
This time he was treated with a generic lipid formulation of
amphotericin B (Fungisome, Lifecare Innovations, India) at a
dosage of 2 mg/kg for 2 weeks, receiving a cumulative dose of
28 mg/kg—a regimen chosen as a less expensive alternative to
AmBisome due to the ﬁnancial contraints of the patient and, with
respect to the low dose used, to the lack of published safety data
and non-inferiority studies of higher doses of this speciﬁc
amphotericin B preparation compared with AmBisome in treating
VL3. The patient appeared to respond well and was discharged
again as an initial cure.
Six months later the patient presented yet again, reporting
four weeks of malaise and fatigue despite continued adherence
with ART. On examination he demonstrated splenomegaly 6 cm
below the costal margin, a hemoglobin of 9.9 gm/dl and CD4 count
of 77 cells/uL, and a plasma HIV viral load of 63 copies/ml. The
repeat bone marrow aspirate revealed a high density of L.D. bodies.
Considering his history of multiple relapses after various
amphotericin B preparations, and the initial treatment failure
with miltefosine, the patient was admitted and treated with a
combination regimen of concurrent AmBisome in 6 doses of
5 mg/kg spread over 14 days (total dose 30 mg/kg) and oral
miltefosine 50 mg twice daily for 14 days. The treatment was
well-tolerated with no adverse events or biochemical marker
deterioration, and the patient was discharged with an initial
cure. His condition improved over the subsequent 12 months,
as evidenced by sustained improvement in CD4 counts of
316 cells/uL, 421 cells/uL and 451 cells/uL at the 3-, 6- and
12-month follow-ups, respectively. At 18 months, the patient
continued to be symptom-free and showed weight gain,
improved hemoglobin level and complete regression of
hepato-splenomegaly.
3. Discussion
This case illustrates the substantial challenges in treating HIV
and Leishmania co-infection, in particular the common problem
of multiple relapses and highlights the unsuitability of using
single-drug regimens in this group of patients. Both HIV and VL
affect T-cell-mediated immunity and are thought to act synergis-
tically to reduce the effectiveness of patients’ immune responses.
This may in part explain why co-infection with Leishmania and HIV
is associated with higher relapse rates of VL, delayed response to
ART, and higher HIV viral loads. Furthermore, co-infected patients
may have atypical clinical presentations of leishmaniasis and are
also more likely to have false negative results when tested for VL
with current standard rapid diagnostic kits4.
In 2010, a WHO expert committee recommended a single dose
of 10 mg/kg liposomal amphotericin B as ﬁrst-line treatment for VL
in the Indian subcontinent1. However, the efﬁcacy of this regimen
in HIV/VL patients remains untested, and indeed highlights the
absence of evidence on effective treatments for this co-infection.
20 mg/kg liposomal amphotericin B monotherapy has been used
relatively successfully in the Indian setting; however, co-infectedpatients treated with this regimen showed far higher relapse and
early mortality rates compared to VL patients not known to be
infected with HIV2,5. In the Ethiopian setting, high-dose mono-
therapy with 30 mg/kg liposomal amphotericin B was associated
with a 32% parasitological failure rate in HIV-VL co-infected
patients2. In such cases, repeated treatment with monotherapies
could potentially lead to increased resistance and treatment
failures, as has already been described with oral miltefosine in the
Indian subcontinent. Meanwhile, resistance mechanisms to
amphotericin B deoxycholate have already been detected in
clinical isolates of L.donovani.
Based on the synergistic properties of liposomal amphotericin B
and miltefosine, the compassionate use of this combination has
been suggested for co-infected patients who have experienced
multiple relapses of VL4. The patient described here was admitted
and treated with a combination of liposomal amphotericin B
(AmBisome) in 6 doses of 5 mg/kg spread over 14 days (total dose
30 mg/kg) and oral miltefosine 50 mg twice daily for 14 days.
Lower doses of this combination had been shown to be safe and
effective in immunocompetent patients in the Indian context3, and
this regimen allowed the entire treatment to be administered
under close inpatient supervision but without an extended patient
stay, which could have major economic beneﬁts for typical VL
patients in India.
The CD4 count remained persistently low in this patient
despite strict adherence to ART over a 9-month period during
which he relapsed and was treated twice for VL. At initiation of
the ﬁnal treatment round with combination therapy, his CD4
count (77 cells/uL) was the lowest it had been since ART was
initiated, yet still with a very low viral load.
Following treatment with the combination regimen, the patient
remained relapse-free 18 months later and has sustained a CD4
count > 350cells/uL. This outcome suggests that the recovery of
immune function which allowed ﬁnal cure of VL was not solely
attributable to control of HIV, but also partly to effective treatment
of VL by the selected drug combination. This, in turn, may have
broken the vicious cycle of synergy which HIV/VL co-infection has
on the immune and haematopoetic system.
The complexity of recognizing the special needs of co-infected
patients should not be underestimated, and region-speciﬁc
guidelines need to be developed by the appropriate national
programs to recognize the problem and support physicians in
managing this very challenging scenario. Indeed, all HIV patients
with a history of spending signiﬁcant periods of time in VL-
endemic areas should be screened for VL, and conversely, all
patients diagnosed with VL should be screened for HIV. Addition-
ally, the use of monotherapy in these patients, given their high risk
of relapse, should be reconsidered.
In conclusion, this instructive case suggests that low-dose
liposomal amphotericin B, lipid complex amphotericin B and
28-day miltefosine monotherapies may lead to treatment failure
in HIV/VL co-infected patients, especially those with low CD4
counts. In contrast, combination therapy with liposomal
amphotericin B (30 mg/Kg) and miltefosine (100 mg/day for
14 days) may have a higher chance of successful outcome. In the
longer term, appropriate management of HIV/VL co-infected
patients may have an important role in reducing the parasite
reservoir, which in turn is crucial for success in the ultimate goal
of disease elimination.
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